亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Has the risk of liver re‐transplantation improved over the two decades?

医学 肝移植 危险系数 肝病 队列 置信区间 内科学 比例危险模型 移植 外科
作者
Miho Akabane,Yuki Bekki,Yuki Imaoka,Yosuke Inaba,Carlos O. Esquivel,Allison J. Kwong,Marc L. Melcher,Kazunari Sasaki
出处
期刊:Clinical transplantation [Wiley]
卷期号:37 (12)
标识
DOI:10.1111/ctr.15127
摘要

Abstract Background Despite advancements in liver transplantation (LT) over the past two decades, liver re‐transplantation (re‐LT) presents challenges. This study aimed to assess improvements in re‐LT outcomes and contributing factors. Methods Data from the United Network for Organ Sharing database (2002–2021) were analyzed, with recipients categorized into four‐year intervals. Trends in re‐LT characteristics and postoperative outcomes were evaluated. Results Of 128,462 LT patients, 7254 received re‐LT. Graft survival (GS) for re‐LT improved (91.3%, 82.1%, and 70.8% at 30 days, 1 year, and 3 years post‐LT from 2018 to 2021). However, hazard ratios (HRs) for GS remained elevated compared to marginal donors including donors after circulatory death (DCD), although the difference in HRs decreased in long‐term GS. Changes in re‐LT causes included a reduction in hepatitis C recurrence and an increase in graft failure post‐primary LT involving DCD. Trends identified included recent decreased cold ischemic time (CIT) and increased distance from donor hospital in re‐LT group. Meanwhile, DCD cohort exhibited less significant increase in distance and more marked decrease in CIT. The shortest CIT was recorded in urgent re‐LT group. The highest Model for End‐Stage Liver Disease score was observed in urgent re‐LT group, while the lowest was recorded in DCD group. Analysis revealed shorter time interval between previous LT and re‐listing, leading to worse outcomes, and varying primary graft failure causes influencing overall survival post‐re‐LT. Discussion While short‐term re‐LT outcomes improved, challenges persist compared to DCD. Further enhancements are required, with ongoing research focusing on optimizing risk stratification models and allocation systems for better LT outcomes.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
轻松冰淇淋完成签到,获得积分10
刚刚
周周粥完成签到 ,获得积分10
3秒前
共享精神应助踏实凡阳采纳,获得10
4秒前
元宝团子完成签到,获得积分10
6秒前
9秒前
爆米花应助调皮饼干采纳,获得10
10秒前
12秒前
春天的粥完成签到 ,获得积分10
13秒前
汉堡包应助pepe采纳,获得10
13秒前
完美小蘑菇完成签到 ,获得积分10
15秒前
16秒前
踏实凡阳发布了新的文献求助10
19秒前
涔岑cen发布了新的文献求助10
20秒前
21秒前
23秒前
123456发布了新的文献求助10
25秒前
25秒前
28秒前
oleskarabach发布了新的文献求助10
28秒前
29秒前
彩色亿先完成签到 ,获得积分10
31秒前
贰壹完成签到 ,获得积分10
42秒前
涔岑cen完成签到,获得积分10
48秒前
邓明完成签到,获得积分10
58秒前
58秒前
完美世界应助邓明采纳,获得10
1分钟前
123456发布了新的文献求助10
1分钟前
oleskarabach完成签到,获得积分20
1分钟前
1分钟前
科研通AI6.2应助Ding采纳,获得10
1分钟前
oleskarabach发布了新的文献求助10
1分钟前
123456发布了新的文献求助10
1分钟前
1分钟前
1分钟前
1分钟前
隐形曼青应助123456采纳,获得10
1分钟前
1分钟前
剑八发布了新的文献求助10
1分钟前
情怀应助剑八采纳,获得10
1分钟前
庞喜存v发布了新的文献求助10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Handbook of pharmaceutical excipients, Ninth edition 5000
Aerospace Standards Index - 2026 ASIN2026 3000
Polymorphism and polytypism in crystals 1000
Signals, Systems, and Signal Processing 610
Discrete-Time Signals and Systems 610
T/SNFSOC 0002—2025 独居石精矿碱法冶炼工艺技术标准 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 纳米技术 有机化学 物理 生物化学 化学工程 计算机科学 复合材料 内科学 催化作用 光电子学 物理化学 电极 冶金 遗传学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 6042332
求助须知:如何正确求助?哪些是违规求助? 7791941
关于积分的说明 16237087
捐赠科研通 5188235
什么是DOI,文献DOI怎么找? 2776290
邀请新用户注册赠送积分活动 1759391
关于科研通互助平台的介绍 1642842